Objective: The aim of this study was to determine prognostic value of tumor size and metabolic activity on survival for patients with early stage nonsmall cell lung cancer receiving stereotactic body radiation therapy.
N onsmall cell lung cancer (NSCLC) remains the most common cancer worldwide, and lung cancer is responsible for approximately 1 in 4 cancer deaths. 1 Surgical resection is the standard treatment for NSCLC, but its aggressive nature and often-late presentation can limit the surgical resection effectiveness. With the increase in the aging population and the more liberal use of computed tomography (CT), more patients who are not medically fit for operation are receiving a diagnosis of lung cancer. Patients who are declared having medically inoperable tumor or who refuse surgical resection are candidates for stereotactic body radiation therapy (SBRT), which delivers optimally positioned high-dose radiation beams to minimize surrounding normal tissue damage. 2 The SBRT has been shown to be a successful, if not equivalent, alternative treatment for nonresectable early stage NSCLC. 3 Because SBRT is becoming a more widely accepted alternative standard of treatment, more and more patients with expanded life expectancy will be encountered. In this group, there may be individuals who would benefit from additional therapy in a similar paradigm to those who receive adjuvant therapy after surgery. 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is an imaging modality that takes advantage of tumor properties such as increased glucose metabolism and is reflective of intrinsic metastatic and proliferative potential. 4 The FDG-PET is a valuable tool for initial staging and subsequent assessments and has been suggested to be a prognostic indicator in the treatment of NSCLC. Previous studies have shown that tumors with a higher maximum standardized uptake value (SUV max ) have a poorer overall prognosis with shorter progression-free and overall survival (OS), [5] [6] [7] [8] although the relationship between SUV max and survival is inconsistent. 9, 10 To improve survival in higher risk individuals, it may be helpful to modify treatment plans by including different dosing of radiotherapy or by adding ablative therapies, adjuvant immunotherapy, or chemotherapy. Because all of the options are associated with additional risks, knowledge of the optimal population for alternative strategies is important. In this study, we retrospectively evaluated the prognostic value of the initial tumor size and metabolic activity on overall 2-year survival for patients with early stage NSCLC receiving SBRT with curative intent. Our hypothesis was that a combination of factors to include both size and tumor metabolic activity would better predict survival at 2 years than either factor alone.
MATERIALS AND METHODS
This retrospective Health Insurance Portability and Accountability Act of 1996-compliant study was done under a waiver of consent from our local institutional review board.
Subjects
We performed a retrospective review of all patients who underwent thoracic SBRT for the treatment of lung cancer over a 5-year period from June 2008 through June 2013. During this period, 240 unique patients were treated. The patients were excluded if the positron emission tomography-computed tomography (PET/CT) was not available, was performed at another institution, or was performed more than 2 months before SBRT or if the patient was treated for metastatic lesions or with palliative intent, leaving a total of 100 subjects. All subjects were considered to be at stage I or II (T1-3N0M0) based on the seventh edition of the American Joint Committee on Cancer Lung Cancer Staging Handbook. The 2-year survival outcome was documented via the electronic medical record. For those subjects who could not be confirmed as alive or deceased from the medical record at their 2-year anniversary, a search of the National Death Index (NDI) was performed to determine vital status. The FDG-PET scans were acquired after the patient had fasted for 6 hours and had confirmed blood glucose of lower than 200 mg/dL. The 18 F-FDG 3.5 MBq/kg body weight was administered via intravenous injection. The PET/CT was acquired using a GE Discovery ST PET/CT (GE Health Care, Waukesha, WI) 45 minutes after FDG administration. The CT portion was performed during quiet breathing with the following parameters: 120 kVp, automated tube current modulation with mA range of 10 to 180, noise index of 18, tube rotation time of 0.8 second, pitch of 1.75, and 50-cm field of view with 3.75-mm slice thickness from the eyes to midthigh. Iodinated contrast was not administered. The PET data was acquired after the CT. The PET images were acquired in 3-dimentional mode and iteratively reconstructed by using 21 subsets and 4 iterations. The attenuation correction images fused with the CT image data were displayed in axial, coronal, and sagittal views.
Image Analysis
For each study, the acquired data were retrieved from the PET/CT data archives and reviewed on a GE AW1 workstation. Measurements were then carried out by a single observer (blind). After the tumor was identified on CT attenuation correction images, automatically segmented boundaries were constructed to encompass the primary tumor, and the tumor diameter and volume were obtained. The diameter was recorded as the average of the long axis and perpendicular measure in the short axis. Manual adjustments to the volume were not made. After the CT measurements, the tumor was identified again using both the attenuation correction and fused images, and the following measurements were then recorded: SUV max , SUV average (SUV avg ), and the SUV volume (SUV vol ). The SUV max was recorded as the maximum SUV pixel value within the tumor volume; SUV average was defined as the average SUV measurement within a 1-cm 3 volume surrounding SUV max ; SUV volume was defined as average SUV activity within the entire tumor volume.
Stereotactic Body Radiation Therapy Methods
Treatment simulation was initiated by a 4-dimensional CT through the thorax and subdivided into 10 bins through the respiratory phase. The images were then delivered to the treatment planning system (PINNACLE 9.0, Philips Healthcare). The internal target volume was planned by a radiation oncologist to delineate and contain all respiratory motion of the tumor. A set up margin of 5 mm was added to the internal target volume resulting in the planning target volume.
Prescription doses were either 50 Gy in 5 fractions or 48 Gy in 4 fractions, with each fraction separated by 2 to 3 days and no more than 2 fractions in 1 week. Initial radiographic follow-up occurred between 1 and3 months after the completion of treatment either with CT or PET/CT. This was followed by CT at 6-month intervals for a total of 2 years.
Evaluation of Patient Outcomes
For the purpose of our study, the OS was assessed at 2 years after the start of SBRT. For all patients in whom a definitive outcome at 2 years could not be ascertained from the medical record, a search of the NDI was performed. The recorded date of death was used in survival analysis. Those who could not be confirmed as deceased were presumed to be alive at the 2-year anniversary.
Statistical Analysis
Summary statistics, including mean or median, SD, and range were used to describe the distributions of continuous variables. Categorical variables were tabulated and reported using percentages. The primary outcome was OS, defined as the time from SBRT to death (or censored at the last known date the patient was alive). Kaplan-Meier estimation was used to calculate median survival and 2-year survival rates with 95% confidence intervals (CIs). Comparisons of survival curves were performed using log-rank tests and Cox regression. Comparisons were based on binary versions of tumor size and PET/CT where a small versus large tumor was defined as 2 cm or shorter vs. longer than 2-cm diameter; the tumors were categorized as low metabolizing if SUV max is 5 or lower versus SUV max is higher than 5. We also considered a tumor diameter cutoff of 3 cm but opted for the 2-cm cutoff as described in the Results section. The final Cox regression model included main effects of both SUV max and tumor size, as well as their interaction. Proportional hazards were tested using graphical displays and were found to adequately meet the assumption. Inferences were based on hazard ratios (HRs) with an α level set at 0.05.
RESULTS
The 100 NSCLC patients (37 female, 63 male) were included in this study, with an average age of 75.8 years (range, 51-95 years). Tumors ranged in size from 0.5 to 8.0 cm, with a median size of 2.2 cm with tumor size as follows: 46 nodules were less than 2 cm, 24 were between 2 and 3 cm (70% were T1 tumors), and 30 were longer than 3 cm. With regard to outcomes, 11 subjects did not have definitive documentation of vital status at the 2-year anniversary. Most subjects had a tissue diagnosis of lung cancer (n = 96). In cases where tissue could not be safely obtained, the patients were discussed at a lung cancer multidisciplinary tumor board, and treatment decision was made based on a very high likelihood of cancer. In 3 of these 4 cases, the SUV max was higher than 5. Demographic and tumor characteristics are listed in Tables 1 and 2 .
Tumor Size Versus Survival
Tumor size was related to outcome because tumors with a diameter of 2 cm or shorter had a median OS of 40 months and a 2-year OS of 74% (95% CI, 0.62-0.80; Fig. 1 ) after SBRT treatment, whereas tumors with a diameter of longer than 2 cm had a median survival of 27 months and a 2-year OS of 59% (95% CI, 0.47-0.74). The estimated HR for tumors with diameter longer than 2 cm versus shorter than or equal to 2 cm was 1.85 (P = 0.039).
Increasing the tumor size cut point to 3 cm resulted in a similar median OS of 34.7 months and 2-year survivals of 70% and 57%, respectively, but the differences were not statistically significant (HR = 1.22, P = 0.52). Because of this, a size cut point of 2 cm was carried forward for further analysis.
SUV Versus Survival
A similar outcome was noted with SUV max, SUV avg , and SUV vol where lower values were associated with better outcomes (Fig. 2 ). An SUV max of 5 or lower had a median OS of 58.6 months and 2-year OS of 79% (95% CI, 0.66-0.94), whereas an SUV max of higher than 5 had a median survival of 27.0 months and 2-year survival of 60% (95% CI, 0.48-0.72). The HR comparing patients with high SUV max versus those with low SUV max was 2.07 (P = 0.025). Estimates of median and 2-year survival were similar for SUV avg , SUV vol , and SUV max when a cutoff of 5 was used (results not shown). Because there was no difference in associations between OS and SUV max , SUV avg , and SUV vol , SUV max was carried forward for further analysis.
Combining Size and SUV Versus Survival
Results from the Cox regression demonstrate that the interaction term was not significant (P = 0.7), implying that the effect of high metabolism on OS is similar among patients with small tumors and those with large tumors. Combining tumor size and SUV max showed that small tumors regardless of SUV max and large tumors with SUV max of lower than 5 had similar survival distributions, whereas large tumors with SUV max higher than 5 had worse outcomes (Fig. 3) . Using small tumors (≤2 cm) with low SUV max (≤5) as a reference, the HR for large tumors with low SUV max was 1.55 (P = 0.43). Comparing small tumors with high SUV max to small tumors with low SUV max , the HR was 1.80 (P = 0.24). Only large tumors with high SUV max were statistically significant from small tumors with low SUV max with an HR of 3.47 (P = 0.007) (Fig. 4 and Table 3 ).
DISCUSSION
Although tumor size is often used to guide the need for adjuvant therapy for surgically resected tumors, there is no such guidance for patients treated with SBRT. Because many of these are medically inoperable because of advanced age and comorbidities, they are often not candidates for systemic therapy. Nonetheless, advances in chemotherapy and immunotherapy raise the hope that appropriate individuals may benefit from adjuvant therapy beyond SBRT. Metabolic activity can also play a role in prognosis, although its utility is less well defined owing to measurement variability and a lack of generalizability across sites. However, with a lack of consistent evidence demonstrating any concrete association between metabolic activity and prognosis with SBRT, the extent of this PET/CT measurement has yet to be fully explored and defined.
Our results show that patients with the combination of both large size and high metabolic activity are at greater risk of death than patients with neither or a single risk factor. Using both tumor characteristics in combination was shown to be a superior predictive value than either alone. The findings are important because they define a subgroup of patients who may benefit from adjuvant therapy in a paradigm similar to those treated surgically. Whether survival can be improved with adjuvant therapies in this group remains to be determined. Several studies to date have shown that SUV max does demonstrate a statistically significant prognostic value in the treatment of early stage NSCLC with SBRT. 6, 7, 11, 12 Horne et al 5 found that the SUV max is a statistically significant predictor of OS and progression-free survival in early stage NSCLC, whereas other studies also found that SUV max is a significant prognosticator for OS. 5, 6, 12 Moreover, a study performed by Takeda et al 8 demonstrated that SUV max was a significant predictor of disease-free survival, OS, and local progression. Yamamoto et al 10 sought to improve pretreatment SUV max values by correcting for partial volume effect and motion artifact. Despite registering higher SUV max when correcting for these factors, the corrected SUV max did not improve local control prediction, and the tumor size remained more relevant.
More recently, Satoh et al 13 assessed the prognostic value of tumor volume, attenuation, and SUV max and found that both volume of 2.5 cm 3 or more and mean attenuation of −120 Hounsfield units or more were better predictors of OS. They did not, however, assess whether using a combination of these features would predict a unique group that might benefit from additional therapy.
Despite this, some studies are not able to produce the same conclusions regarding the relevance of SUV max values. 9 A metaanalysis in 2009 found that SUV max on preoperative PET/CT was a poor prognostic indicator, and another meta-analysis in 2008 also concluded that the primary tumor SUV max was a suboptimal prognosticator in stages I to III NSCLC. 14, 15 They found it difficult to draw concrete conclusions because of the number of heterogeneous factors including SUV max thresholds and research designs that had been used. In addition, it does not seem that an SUV max threshold is necessarily generalizable across different institutions.
Total lesion glycolysis (TLG) has been advocated as a better measure of metabolic activity by multiplying the SUV avg within the entire tumor by the tumor volume and has been shown to help predict outcome in both surgically resected patients 16 and those treated with SBRT. 11 Despite having the advantage of combining metabolic activity and size into 1 measure, TLG has not been shown to be superior to SUV max in predicting outcome. Only in a subset of tumors of longer than 3 cm treated with SBRT did TLG better predict survival. 11 This corroborates our finding that the combination of larger tumor size associated with higher metabolic activity represents a distinct risk for recurrence. We chose not to perform TLG in our population owing to the inherent difficulties in obtaining an accurate volume measurement on the attenuation correction CT. We believe that the combination of diameter and SUV max is a reasonable surrogate for TLG, while being both easier and faster to obtain. Our study has several limitations. This is a retrospective study conducted over several years, and we cannot account for effects of SBRT improvements and experience over time. Because we were not always able to account for vital status at 2 years, we performed an NDI search in an effort to improve the end point. This is an imperfect strategy that may not account for all events, and it is possible that some deaths were not captured. The SUV values were all calculated for the same PET/CT scanner, and therefore, optimal cut points may differ from site to site. Unfortunately, our sample size is relatively small. Another limitation that we encountered was in the acquisition of SUV values for tumors of 2 cm or shorter. We do not routinely use respiratory gating, which may result in an underestimation of SUV. Although the use of respiratory gating would undoubtedly give higher SUV values, we believe this would simply change cut-off thresholds rather than provide additional information. And finally, because of patients' medical conditions, many did not undergo formal mediastinal staging. Although it is possible that some subjects were therefore understaged, this may be mitigated by the incidental prophylactic nodal radiation that occurred during SBRT. 17 In a recent study by Giuliani et al, 18 they found that regional recurrence was associated with higher SUV max value in the primary tumor and therefore suggested that routine nodal sampling with endoscopic bronchial ultrasound should be considered in these higher risk patients.
In conclusion, both tumor size and tumor metabolic activity alone are associated with increased risk of death. A model that accounts for tumor diameter and metabolic activity is superior for predicting 2-year survival and identifying a subgroup of patients for whom both OS and 2-year survival are statistically worse. The results suggest a subgroup population that may benefit from clinical trials evaluating the need for radiation dose escalation approaches or adjuvant chemo or immune therapy. 
